Suppr超能文献

相模霉素及相关氨基糖苷类抗生素:发酵与生物合成。I. 相模小单孢菌阻断突变体的生物合成研究。

Sagamicin and the related aminoglycosides: fermentation and biosynthesis. I. Biosynthetic studies with the blocked mutants of Micromonospora sagamiensis.

作者信息

Kase H, Odakura Y, Nakayama K

出版信息

J Antibiot (Tokyo). 1982 Jan;35(1):1-9. doi: 10.7164/antibiotics.35.1.

Abstract

The mutants blocked in the gentamicin C1 production were derived from a sagamicin producing strain of Micromonospora sagamiensis. The intermediates produced by these mutants were isolated and properly identified. Comparing the biotransformation activities in the resting cells of the mutants with those of a DOS idiotroph, KY 11525, the blocked steps in sagamicin and gentamicin biosynthesis were proposed in each mutant. Mutant KY 11564 was found to produce gentamicin C2a (C-6'-epimer of gentamicin C2) together with gentamicin C1a and sagamicin. KY 11525 transformed gentamicin C2a into C2 and C1, whereas KY 11564 lacked the activity. KY 11565 produced gentamicin X2 and antibiotic G-418, and lacked 6'-amino substitution activities. KY 11566 appeared to be partially blocked in 6'-N-methylation activities, and the major products were gentamicin C2a and C1a. From these results, sagamicin biosynthesis in M. sagamiensis is discussed.

摘要

阻断庆大霉素C1产生的突变体源自产相模霉素的相模链霉菌菌株。分离并正确鉴定了这些突变体产生的中间体。通过比较这些突变体静息细胞与营养缺陷型菌株KY 11525的生物转化活性,推测了每个突变体中相模霉素和庆大霉素生物合成中的阻断步骤。发现突变体KY 11564除了产生庆大霉素C1a和相模霉素外,还产生庆大霉素C2a(庆大霉素C2的C-6'-差向异构体)。KY 11525可将庆大霉素C2a转化为C2和C1,而KY 11564缺乏该活性。KY 11565产生庆大霉素X2和抗生素G-418,并且缺乏6'-氨基取代活性。KY 11566似乎在6'-N-甲基化活性方面部分受阻,其主要产物是庆大霉素C2a和C1a。根据这些结果,对相模链霉菌中相模霉素的生物合成进行了讨论。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验